Surrozen, Inc./DE Stock Split Ratio
Surrozen, Inc./DE (SRZN) reported Stock Split Ratio of 17.56% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2023-03-31
- Surrozen, Inc./DE stockholders' equity note, stock split, conversion ratio for the quarter ending 2022-03-31 was 17.56%.
- Surrozen, Inc./DE stockholders' equity note, stock split, conversion ratio for fiscal 2022 was 17.56%, a 0.00% change from fiscal 2021.
- Surrozen, Inc./DE stockholders' equity note, stock split, conversion ratio for fiscal 2021 was 17.56%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 3 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 6 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 9 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|---|---|---|
| 2022-12-31 | 17.56% 10-K · filed 2023-03-31 | ||||
| 2022-09-30 | 17.56% 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | 17.56% 10-Q · filed 2022-08-11 | ||||
| 2022-03-31 | 17.56% 10-Q · filed 2022-05-11 | ||||
| 2021-12-31 | 17.56% 10-K · filed 2022-03-28 | ||||
| 2021-09-30 | 17.56% 10-Q · filed 2021-11-15 | ||||
| 2021-08-31 | 17.56% 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |